For self-funded employers, specialty infusion drugs are a major and rapidly growing cost driver—accounting for over half of all specialty drug spending. The problem isn’t just the price of the drugs, but the hidden provider markups, which often exceed 400%, embedded within the “buy-and-bill” system. This lack of transparency can lead to millions in avoidable spending.
